StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Bosulif (bosutinib by Quarter

Bosulif (bosutinib — CML) — International revenues ($M) ($M)

QuarterlyAnnual

Pfizer Bosulif (bosutinib: $25M in Q2 2026, down 21.9% from a year earlier.

Latest, Q2 2026
25
Period ended Jun 28, 2026
Change on a year earlier
-21.9%
32 in Q2 2025
History
39 quarters
Since Q4 2016
Sources
35
Documents cited below

Where the Q2 2026 figure comes from

“|| Bosulif | 113 | 149 | (24%) | (24%) | 88 | 116 | (24%) | 25 | 32 | (24%) | (22%)”

Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗

Reported in Form 8-K Revenue Tables & Form 10-Q / 10-K Segment Footnotes.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedBosulif (bosutinib — CML) — International revenues ($M) ($M)Year on yearSource
Q2 2026Jun 28, 202625-21.9%Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Q1 2026Mar 29, 202621-32.3%Form 8-K (Earnings / Guidance Release) (pfe-3292026xex99.htm, filed 2026-05-05) ↗
Q4 2025Dec 31, 202526-40.9%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Q3 2025Sep 28, 202534-29.2%Form 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗
Q2 2025Jun 29, 202532-34.7%Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Q1 2025Mar 30, 202531-29.5%Form 8-K (Earnings / Guidance Release) (pfe-3292026xex99.htm, filed 2026-05-05) ↗
Q4 2024Dec 31, 202444-29.0%Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Q3 2024Sep 29, 202448+4.3%Form 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗
Q2 2024Jun 30, 202449+2.1%Form 8-K (Earnings / Guidance Release) (pfe-06292025xex99.htm, filed 2025-08-05) ↗
Q1 2024Mar 31, 2024440.0%Form 8-K (Earnings / Guidance Release) (pfe-03302025xex99.htm, filed 2025-04-29) ↗
Q4 2023Dec 31, 202362+19.2%Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗
Q3 2023Oct 1, 202346-2.1%Form 8-K (Earnings / Guidance Release) (pfe-9292024xex99.htm, filed 2024-10-29) ↗
Q2 2023Jul 2, 202348-12.7%Form 8-K (Earnings / Guidance Release) (pfe-6302024xex99.htm, filed 2024-07-30) ↗
Q1 2023Apr 2, 202344-4.3%Form 8-K (Earnings / Guidance Release) (pfe-3312024xex99.htm, filed 2024-05-01) ↗
Q4 2022Dec 31, 202252+2.0%Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
Q3 2022Oct 2, 202247+6.8%Form 8-K (Earnings / Guidance Release) (pfe-10012023xex99.htm, filed 2023-10-31) ↗

Breakdown

What makes up bosulif (bosutinib

Cite this data

StockData. (2026). Pfizer Bosulif (bosutinib ($M), quarterly Q4 2016–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/bosulif-intl

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.